China's Simcere to be taken private by Chairman for $495 mln
Aug 28 (Reuters) - China's Simcere Pharmaceutical Group said it agreed to be bought by a consortium that includes its founder-chairman Jinsheng Ren in a deal worth $495.4 million.
The company said it will receive $9.66 per American depositary share (ADS), representing a premium of about 3 percent over Tuesday's close on the New York Stock Exchange.
The consortium already owns about 78 percent of Simcere's outstanding shares and had made an offer worth $9.56 per ADS to buy the company on March 11.
- Insight: How U.S. spying cost Boeing multibillion-dollar jet contract
- Exclusive: Secret contract tied NSA and security industry pioneer |
- With Fed out of the way, what's next on Wall Street?
- Seagram chairman, WJC head Edgar Bronfman dead at 84
- U.S. aircraft hit by gunfire in South Sudan as conflict worsens |